{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:28:29Z","timestamp":1782458909512,"version":"3.54.5"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,8,15]]},"DOI":"10.2169\/internalmedicine.8507-21","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T22:08:26Z","timestamp":1642025306000},"page":"2463-2469","source":"Crossref","is-referenced-by-count":10,"title":["Pembrolizumab-induced Focal Pancreatitis Diagnosed by Endoscopic Ultrasound-guided Fine-needle Aspiration"],"prefix":"10.2169","volume":"61","author":[{"given":"Juri","family":"Ikemoto","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Serikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsushima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kiyoshita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Arihiro","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sharon E, Streicher H, Goncalves P, Chen HX. Immune checkpoint inhibitors in clinical trials. Chin J Cancer 33: 434-444, 2014.","DOI":"10.5732\/cjc.014.10122"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387: 1540-1550, 2016.","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255-265, 2017.","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"4","unstructured":"4. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714-1768, 2018."},{"key":"5","unstructured":"5. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. J Clin Oncol 38: 1-10, 2020."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin&apos;s lymphoma. N Engl J Med 372: 311-319, 2015.","DOI":"10.1056\/NEJMoa1411087"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520, 2015.","DOI":"10.1056\/NEJMoa1500596"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60: 190-209, 2016.","DOI":"10.1016\/j.ejca.2016.02.025"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Tanaka T, Sakai A, Shiomi H, et al. An autopsy case of severe acute pancreatitis induced by administration of pazopanib following nivolumab. Pancreatology 21: 21-24, 2021.","DOI":"10.1016\/j.pan.2020.11.002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Alabed YZ, Aghayev A, Sakellis C, Van den Abbeele AD. Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET\/CT. Clin Nucl Med 40: e528-e529, 2015.","DOI":"10.1097\/RLU.0000000000000940"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Ikeuchi K, Okuma Y, Tabata T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report. Lung Cancer 99: 148-150, 2016.","DOI":"10.1016\/j.lungcan.2016.07.001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kakuwa T, Hashimoto M, Izumi A, Naka G, Takeda Y, Sugiyama H. Pembrolizumab-related pancreatitis with elevation of pancreatic tumour markers. Respir Case Rep 8: e00525, 2020.","DOI":"10.1002\/rcr2.525"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Saito H, Ono K. Nivolumab-induced pancreatitis: an immune-related adverse event. Radiology 293: 521, 2019.","DOI":"10.1148\/radiol.2019191603"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tanaka T, Sakai A, Kobayashi T, et al. Nivolumab-related pancreatitis with autoimmune pancreatitis-like imaging features. J Gastroenterol Hepatol 34: 1274, 2019.","DOI":"10.1111\/jgh.14620"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Rawson RV, Robbins E, Kapoor R, Scolyer RA, Long GV. Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas. Eur J Cancer 82: 167-170, 2017.","DOI":"10.1016\/j.ejca.2017.05.042"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tanaka S, Asakawa R, Komuta K, et al. A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma. Respir Med Case Rep 31: 101266, 2020.","DOI":"10.1016\/j.rmcr.2020.101266"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ueno M, Tsuji Y, Yokoyama T, et al. A case of fatal immune checkpoint inhibitor-related pancreatitis. Intern Med 60: 3905-3911, 2021.","DOI":"10.2169\/internalmedicine.7366-21"},{"key":"18","doi-asserted-by":"crossref","first-page":"e59125","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"18. Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3: e59125, 2018.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Widmann G, Nguyen VA, Plaickner J, Jaschke W. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep 5: 59, 2016.","DOI":"10.1007\/s40134-017-0256-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yoshikawa Y, Imamura M, Yamaoka K, et al. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. Clin J Gastroenterol 14: 283-287, 2021.","DOI":"10.1007\/s12328-020-01287-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fujii M, Ozato T, Mizukawa S, et al. A rare case of immunotherapy-induced cholangitis and gastritis. Clin J Gastroenterol 13: 1083-1090, 2020.","DOI":"10.1007\/s12328-020-01218-0"},{"key":"22","unstructured":"22. NCCN Clinical Practice Guidelines in Oncology - Management of Immunotherapy-Related Toxicities. Version 2.2021 [Internet]. [cited 2021 Mar 26]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/16\/61_8507-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T03:17:14Z","timestamp":1660965434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/16\/61_8507-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":22,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8507-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"article-number":"8507-21"}}